Top developments in clinical cardiac electrophysiology–2025 Authors: Brian Olshansky Published: 2026 Key Findings ▪There are major advances in atrial fibrillation management and detection. There are major advances in atrial fibrillation management and detection. ▪Conduction system (left bundle branch area) and leadless pacing are mainstream. Conduction system (left bundle branch area) and leadless pacing are mainstream. ▪Management of athletes with syncope and prior cardiac arrest has changed. Management of athletes with syncope and prior cardiac arrest has changed. ▪Advances in premature ventricular contraction and ventricular tachycardia ablation have taken place. Advances in premature ventricular contraction and ventricular tachycardia ablation have taken place. ▪Artificial intelligence and wearable monitors and defibrillators have a future in electrophysiology. Artificial intelligence and wearable monitors and defibrillators have a future in electrophysiology. The following are among the top developments in cardiac electrophysiology (EP) in 2025. This has been a busy year filled with emerging therapeutic interventions and insights into novel diagnostic approaches. As is often the case in EP, things move quickly. Several important advances may have been left out inadvertently or for space. Advances in atrial fibrillation ablation-pulsed field ablation, and anticoagulation Pulsed field ablation (PFA) has changed the landscape of atrial fibrillation (AF) ablation. Ablation is now faster, possibly safer, and better. There are several studies of importance. One is Multicenter Survey of Methods, Efficacy, and Safety of the Postapproval Clinical Use of Pulsed Field Ablation in the United States (MANIFEST US), a registry of ∼40,000 individuals who have undergone PFA.1 PFA is safe and effective, at least for the short term. Other data indicate PFA may be better than other ablation techniques; this area is evolving rapidly. Consider that AF ablation is demonstrably better than a sham intervention. The Pulsed-Field Ablation Vs. Sham Ablation to Treat AF (PFA-SHAM)2 and Pulmonary Vein Isolation vs. Sham Intervention in Patients With Symptomatic AFib (SHAM-PVI)3 trials, compared PVI to a placebo intervention. Not surprisingly, PVI is more effective in reducing AF, but these trials also show that sham has some value. Therefore, benefits of ablation over sham can now be calibrated. The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial considered the long-term need for oral anticoagulation in individuals undergoing catheter ablation of AF with a successful ablation result.4 The risk for thromboembolic events after successful ablation was extraordinarily small as shown in this well-designed trial suggesting that long-term anticoagulation may be able to be stopped. The Anticoagulation One year after Ablation of Atrial Fibrillation in Patients with Atrial Fibrillation (ALONE-AF) trial, a smaller randomized trial, had a combined primary end point of stroke, systemic embolism, and major bleeding. These data further support the concept that patients who are free from AF at 1 year post-ablation can safely discontinue anticoagulation.5 Lifestyle changes and atrial fibrillation-outcomes matter The relationship between cardiovascular disease and lifestyle changes has gained focus.6, 7, 8 Outcomes matter (not AF, per se); mortality, stroke and issues such as heart failure and AF hospitalizations are valuable, important, end points. Data to support AF ablation to affect mortality or even heart failure hospitalization remain controversial except for a few studies. Catheter Ablation vs. AADs and Risk Factor Modification (PRAGUE 25) compared lifestyle management to PVI.9 With lifestyle management (ie, weight loss, reduction in alcohol consumption, and exercise), there is a marked improvement in quality-of-life and benefits in outcome measures (NT-pro BNP, CRP, triglycerides and VO2 max) similar to that seen with PVI alone. AF burden was reduced in both groups but much more so in the ablation arm. HbA1c was reduced in the lifestyle group but not the ablation group. So, there may be tremendous benefits in lifestyle management on top of ablation. The Does Coffee Eliminate Atrial Fibrillation? (DECAF) trial10 looked at the use of and the effects of coffee consumption on AF. Coffee is nothing to worry about for the average individual with AF. The importance of weight loss with drug intervention has been evaluated. There are two trials of importance; one is the metformin before catheter ablation for AF (Metformin Reduces Arrhythmia Recurrence After AF Ablation in Overweight, Non-diabetic Patients [META-AF]) trial, a trial of metformin to test if recurrence rates after AF ablation are improved with metformin and the Dapagliflozin After Atrial Fibrillation Ablation (DARE AF) trial11 which tested if a sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, reduced burden of early recurrence of AF and flutter after ablation. These trials showed discrepant results. So far, no specific non-antiarrhythmic drug definitively affects outcomes after ablation for patients who are obese, or, perhaps, even those who are not. Device-detected atrial fibrillation Device-detected AF12 remains a complex issue. Indeed, almost any small amount of AF is associated for recurrent or initial episodes of stroke.13 Patients with a high CHA2DS2-VASc score, who have a small burden of device-detected AF, do have a higher risk but, nevertheless, that risk is small.14 The best way to define burden remains obscure15 but emerging data indicate a relationship of AF burden to outcomes. The DEFINE Atrial Fibrillation (DEFINE-Afib) Study used continuous monitoring to assess the influence of AF burden and patterns on patient symptoms and health care utilization.16 It is difficult to determine exactly who needs to be anticoagulated because there is a risk of anticoagulation17 and a cost. However, there can be a benefit even if there is a small burden of AF. Clinical decisions, therefore, need to consider the number needed to treat to obtain a benefit from oral anticoagulation in lieu of the risks of treatment; this is a difficult needle to thread.12 The challenge now is not only how to best assess AF burden in the real world but also how to best reconcile years of data using AF recurrence as an outcome for nearly all clinical studies involving AF interventions. This has major implications regarding how future studies should be designed. Left atrial appendage occlusion devices-coming to the fore…or not? Many left atrial appendage occlusion devices are now being implanted. Some patients have a single procedure: catheter ablation for AF with atrial appendage occlusion device implant simultaneously. Is this necessary or even a good idea? Maybe this is overdone. The Catheter-Based Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding as Compared with Best Medical Therapy (CLOSURE-AF) trial18 showed that left atrial occlusion devices were not only non-inferior, but they actually were inferior regarding bleeding and stroke compared to rivaroxaban, even in those patients that had high CHA2DS2-VASc scores and were at risk for bleeding. Where things are going regarding left atrial appendage occlusion devices remains uncertain. Dual chamber leadless pacing - what could be next? Dual-chamber leadless pacing has become established, and now standard, but the question remains: How beneficial is this approach and for which patients.19 Then, what is next? There are initial reports of leadless pacing with resynchronization capabilities (left bundle area pacing), but the success rate is not ideal.20 This has only been performed in a few patients as an experimental procedure and devices and techniques will evolve. Conduction system (left bundle branch area) pacing now mainstream Conduction system pacing has become mainstream; some of the data are spectacular. For example, the International Collaborative LBBAP Study (I-CLAS) study has looked at the left ventricular ejection fraction in patients who have a left ventricular ejection fraction <50%. In this study of >2500 patients looking at death or heart failure hospitalization, the results were in favor of left bundle branch area pacing vs cardiac resynchronization therapy pacing.21,22 Likely, left bundle area pacing will become the first-line approach for patients who require ventricular pacing (in lieu of cardiac resynchronization therapy in many instances) or, even, perhaps, for those needing defibrillator implants. Athletes, syncope, and cardiac arrest - shared decision-making The management of athletes who have had syncope or cardiac arrest23 and those who have hypertrophic cardiomyopathy24 or have long QT interval syndrome25 has evolved. The policies in years past were highly restrictive, but new data from large populations of competitive and non-competitive athletes, who are otherwise well-treated, indicate that those with hypertrophic cardiomyopathy who had syncope, and those who have long QT syndrome who had cardiac arrest and have undergone verbal and written plans along with optimal medical therapy may, in many instances, return to play. The risks are no greater than for non-athlete patients with the same conditions. Considering athletes with these underlying conditions, shared decision-making26 becomes very important but the risks may be low. Wearables - self-diagnosis? Regarding wearables and self-diagnoses, a new era is upon us. Wearables are going to be a way to define how patients determine if they have an arrhythmia, if they have AF or some life-threatening cardiac arrhythmic condition.27,28 Data on some of the tools presently available are compelling and suggest that the accuracy can be quite high with a sensitivity between 84%–95% and a specificity of 93%.27, 28, 29, 30, 31 Patient satisfaction with diagnostics and changes in therapy based on self-assessment with wearables is evolving quickly.32 Questions remain: What is the best wearable? Is an electrical recording needed? How many leads? Who interprets the tracings? Is other physiological information required? Can we use photoplethysmography (PPG) alone? Are other parameters needed? How are these data integrated into information regarding comorbid condition? It will be important to define who needs to be treated and who needs to be identified. If AF is found on a wearable and is asymptomatic, is intervention necessary? Is AF seen on a wearable out of the ordinary and important requiring similar risk stratification as an otherwise clinically diagnosed episode? Autonomic conditions - what works, what does not? Two conditions seen frequently in EP practice, postural orthostatic tachycardia syndrome and inappropriate sinus tachycardia, pose diagnostic and therapeutic conundrums. They each represent several underlying etiologies for which therapies are often ineffective and for which mechanisms remain at best uncertain.33 Even a well-accepted definition of “dysautonomia” is surprisingly vague. The concept that an autoantibody could cause these conditions has intrigued many but has now been brought into question as an etiology at all except for a select few. Intravenous immunoglobulin compared to placebo did not show a benefit in patients with postural orthostatic tachycardia syndrome suspected of having an autoantibody cause.34 Specific conditions, such as COVID, may present with unique mechanisms for autonomic dysfunction and present new challenges.35,36 Advances in premature ventricular contraction and ventricular tachycardia ablation Advances continue in identification of patients with premature ventricular contractions and ventricular tachycardia (VT) benefit from ablation. New tools to map and ablate, potentially with the use of artificial intelligence (AI), continue to be developed. Data continue to point to ablation as the most effective and potentially safe method to reduce VT recurrences compared with drug therapy in patients with ischemic and non-ischemic cardiomyopathy. Data from Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2 (VANISH 2) showed that ablation was superior to sotalol for a primary composite end point of death, appropriate implantable cardioverter-defibrillator shock, VT storm and treated sustained VT below the detection limit of the implantable cardioverter-defibrillator. For patients taking amiodarone, efficacy outcomes were similar between ablation and amiodarone.37,38 However, adverse events were more marked in those patients randomized to amiodarone. Ablation for VT has not yet been shown to improve overall survival. Better mapping and ablation techniques may facilitate ablation success. Use of PFA for VT ablation is now being tested.39 Wearable cardioverter defibrillators - they have a role Wearable cardioverter defibrillators (WCD) have an important role in risk reduction and that role is becoming better defined. Data from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) trial that looked at a large population found in a high-risk group, that they used their WCD appropriately and effectively. Many who had an intervention did reasonably well in the long-term. We have not defined which population is going to benefit and exactly who should get the WCD. A randomized, controlled trial of wearable cardioverter defibrillators in a high-risk population would be welcome. Artificial intelligence and EP management - is there a future? AI will transform and revolutionize AI management in many ways. We considered syncope management with AI.40,41 Better ways are needed to identify which patients are at risk and how they should be managed but it is more than that.42,43 AI technology will help guide catheter ablation. AI will fine-tune outpatient management. AI can better define who is at risk for out-of-hospital cardiac arrest. AI may transform interpretation of the electrocardiogram28 or the electrocardiogram in combination with clinical characteristics. AI may help guide the clinician to focus and optimize the history and physical examination and determine who may be at high risk of sudden death. Present tools, including the left ventricular ejection fraction to quantitate risk, may become outdated or be used in collaboration with AI to categorize risk. AI has a tremendous future in assessment, management, therapy delivery, and outcome measurement. Conclusion In the fast-moving field of clinical cardiac AI, 2025 has landed us in a new era of improved management leading to better outcomes for our patients. Disclosures The author has no conflicts of interest to disclose. Acknowledgments Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authorship All authors attest they meet the current ICMJE criteria for authorship. References